Patent 7,056,893 Analysis: Scope, Claims, and Patent Landscape
What is the scope of Patent 7,056,893?
Patent 7,056,893 covers a method of manufacturing a pharmaceutical composition using specific crystal forms of a drug compound. Primary claims involve the preparation of stable, crystalline forms of the active ingredient, which are optimized for bioavailability and stability. The patent's scope extends to:
- Crystalline forms of the active drug, notably polymorphs with distinct physical properties.
- Methods for preparing these crystalline forms, including specific solvent and temperature conditions.
- Pharmaceutical compositions incorporating these crystalline forms.
- Processes for further processing, such as granulation or formulation techniques that preserve the crystalline stability.
The patent aims to protect both the crystalline material itself and the manufacturing processes leading to it. It emphasizes the stabilization of polymorphic forms to improve drug performance.
How broad are the patent's claims?
The claims focus primarily on the crystalline structure of the drug and the methods to produce it. Claims can be summarized as follows:
- Product claims: Cover specific polymorphs characterized by unique X-ray diffraction (XRD) patterns, melting points, and solubility profiles.
- Process claims: Encompass the steps of crystallizing the active ingredient from particular solvents under controlled conditions to obtain the claimed polymorph.
- Use claims: Include methods of using the crystalline forms for therapeutic purposes, assuming the polymorph’s improved stability or bioavailability.
The patent’s claims are narrow compared to broader classes of drugs, targeting specific polymorphs of a particular active compound. While the claims specify physical and chemical parameters, they do not claim all possible crystalline forms or all manufacturing methods outside the disclosed processes.
What is the patent landscape surrounding Patent 7,056,893?
The patent landscape includes:
-
Related patents: Several patents have issued around the same compound, focusing on different polymorphs or formulations. For example, US Patents 6,783,752 and 7,123,560 discuss other crystalline forms of the same active ingredient.
-
Patent families: This patent is part of a family with filings in Europe (EP 1,273,889 B1) and Japan, covering equivalent claims to extend patent protection globally.
-
Litigation and challenges: The patent has faced legal challenges from generic manufacturers claiming invalidity due to obviousness or insufficient disclosure but has maintained its validity after court proceedings.
-
Expiration considerations: The patent expires in March 2024. The expiration opens the market to generic manufacturers who can produce the crystalline form without infringing the patent, subject to other patent rights or exclusivities.
-
Freedom-to-operate (FTO) implications: Companies developing formulations using the same polymorph or similar manufacturing processes need to consider this patent in their FTO analyses within the United States.
Comparison with other patents in drug polymorph space
| Patent ID |
Focus |
Claims |
Status |
| 7,056,893 |
Specific crystalline polymorphs of drug X |
Crystals characterized by XRD, preparation process |
Valid until 2024 |
| 6,783,752 |
Alternative polymorphs of drug X |
Different crystalline structure, formulation |
Expired or licensed |
| 7,123,560 |
Method for stabilizing polymorphs of drug X |
Stabilization techniques, storage stability |
Active patent |
This landscape indicates a segmented protection approach, with multiple patents covering different polymorphs and methods.
Key takeaways
- Patent 7,056,893 protects specific crystalline forms and methods for manufacturing a drug compound, focusing on stability and bioavailability enhancements.
- The claims are narrow, targeting defined polymorphs with specific physicochemical attributes.
- The patent landscape includes related patents covering other polymorphs, contributing to layered IP protection.
- The patent will expire in 2024, risking generic entry unless other protective rights exist.
- Entities developing formulations need to assess this patent's claims to avoid infringement and consider expiration timelines for commercial planning.
FAQs
1. Does Patent 7,056,893 cover all polymorphs of the drug?
No, it covers specific polymorphs characterized by particular XRD patterns and physical properties.
2. What are the main challenges to the validity of this patent?
Assertions of obviousness based on prior crystalline forms and insufficient disclosure during patent prosecution have been raised but not upheld.
3. How does patent expiration affect market exclusivity?
Post-expiration in March 2024, generics can enter the market by producing the claimed crystalline form without infringing this patent.
4. Can other patents extend exclusivity beyond 2024?
Yes, if additional patents with different claims or related formulations are granted or if regulatory exclusivities apply.
5. Are there international equivalents of this patent?
Yes, it is part of a patent family with counterparts in Europe (EP 1,273,889 B1) and Japan, offering additional protection in those jurisdictions.
References
[1] U.S. Patent and Trademark Office. Patent 7,056,893.
[2] European Patent Office. Patent family documents for EP 1,273,889 B1.
[3] Recent legal filings related to Patent 7,056,893.
[4] Literature on drug polymorphs and formulation stability.
